<DOC>
	<DOCNO>NCT00849550</DOCNO>
	<brief_summary>The purpose study determine RAD001 ( everolimus ) help improve standard treatment XELOX-A ( bevacizumab , oxaliplatin , capecitabine ) advance solid tumor .</brief_summary>
	<brief_title>Safety Dosage Study RAD001 ( Everolimus ) Combination With Current Standard Care Treat Advanced Solid Tumors .</brief_title>
	<detailed_description />
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Must 18 year old Must performance status least 70 % ( able carry normal activity ) Must life expectancy least 3 month Must adequate organ marrow function determine lab test Women childbearing potential men must agree use two form contraception Ability willingness sign write informed consent document Histologically confirm solid tumor malignancy metastatic unresectable Pregnant breastfeeding and/or lactate woman Patients receive investigational agent within 28 day first day study drug Patients know CNS metastases History carcinoma within last 5 year ( except nonmelanoma skin cancer , insitu cervical cancer , localize prostate cancer ) Inadequately control hypertension Significant vascular disease Invasion encasement major artery Evidence bleed diathesis coagulopathy Major surgical procedure , open biopsy significant traumatic injury within 28 day prior day 1 study drug Serious illness medical condition History myocardial infarction , unstable angina , cardiac vascular stenting History stroke HIV , Hepatitis C , Hepatitis B serious chronic infection Impairment Gastrointestinal function disease History interstitial lung disease Patients radiation therapy , hormonal therapy , biologic therapy chemotherapy cancer within 28 day receive study drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Advanced Solid Tumors</keyword>
	<keyword>Cancer</keyword>
	<keyword>Capecitabine</keyword>
	<keyword>XELOX</keyword>
	<keyword>Neoplasms</keyword>
	<keyword>Oxaliplatin</keyword>
	<keyword>Bevacizumab</keyword>
	<keyword>RAD001</keyword>
</DOC>